Diabetes-Insulin resistance. Type 2 diabetes mellitus with hyperosmolarity with coma
Conditions
Interventions
Intervention 1: Intervention group: Type 2 diabetic patients received metformin and capsule containing 300 mg magnesium sulphate and 100 mg thiamin. Intervention 2: Control group: Type 2 diabetic pati
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with a definitive diagnosis of type 2 diabetes for more than 5 years by a physician (plasma glucose level greater than 126 mg/dL and HbA1c between 6.5 and 8 percent at least 3 months before the start of the study) Men or women in the age range is over 18 years with a body mass index of 18.5 to 30 kg/m2 . 3 Patients taking metformin Being able to communicate and volunteer to participate in the research. Signature written consent Residence in Isfahan city The possibility of continuous monitoring of patients.
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Smoking and alcohol consumption during study and in the last year Suffering from other underlying diseases such as severe liver failure, kidney failure (serum creatinine more than 4 mg/dL), severe cardiovascular diseases, stroke up to 3 months before the start of the research, cancer, inflammatory diseases, severe infection, and thyroid disorders. Taking drugs such as insulin, immunosuppressive drugs, anti-inflammatories. Taking medicinal supplements containing magnesium, thiamine or a history of allergy to these drugs. Patients with severe ketosis. Change in the type or dose of diabetes medication during the intervention. Patients with poor and inappropriate nutrition and with persistent anemia (hemoglobin less than 6 mg/dL). Patients who consume less than 90% of the tested medication will be excluded from the study Traveling for more than two weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose-. Timepoint: Before intervention and every 3 months. Method of measurement: By using kit and according to the kit instructions.;HbA1c. Timepoint: Before intervention and every 3 months. Method of measurement: By using kit and according to the kit instructions. | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA-IR. Timepoint: Before intervention and every three months. Method of measurement: By using specific kits.;GLUT4 gene expression. Timepoint: Before intervention and every three months. Method of measurement: By using specific kit.;FOXO1 gene expressions. Timepoint: Before intervention and every three months. Method of measurement: By using specific kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBijan Iraj
Esfahan University of Medical Sciences
Outcome results
None listed